The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 16, 2018

Filed:

Apr. 26, 2016
Applicant:

University of Notre Dame Du Lac, Notre Dame, IN (US);

Inventors:

Mayland Chang, Granger, IN (US);

Shahriar Mobashery, Granger, IN (US);

Mijoon Lee, Mishawaka, IN (US);

Assignee:

University of Notre Dame du Lac, South Bend, IN (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); C07K 2/00 (2006.01); C07K 4/00 (2006.01); C07K 5/00 (2006.01); C07K 7/00 (2006.01); C07K 14/00 (2006.01); C07K 16/00 (2006.01); C07K 17/00 (2006.01); A61K 31/38 (2006.01); C07D 331/02 (2006.01); C07D 409/12 (2006.01); A61K 38/48 (2006.01); A61K 38/49 (2006.01);
U.S. Cl.
CPC ...
A61K 31/38 (2013.01); A61K 38/482 (2013.01); A61K 38/4886 (2013.01); A61K 38/49 (2013.01); C07D 331/02 (2013.01); C07D 409/12 (2013.01); C12Y 304/21 (2013.01); C12Y 304/21068 (2013.01); C12Y 304/21073 (2013.01); C12Y 304/24007 (2013.01); C12Y 304/24017 (2013.01); C12Y 304/24023 (2013.01); C12Y 304/24035 (2013.01);
Abstract

The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The disease, disorder, or condition can include, for example, stroke, neurological disorders, or ophthalmological disorders. The treatment can include administering a compound or composition described herein, thereby providing a prodrug compound that metabolizes to an active MMP inhibitor in vivo. The MMP inhibition can be selective inhibition, for example, selective inhibition of MMP-2, MMP-9, and/or MMP-14. Thus, the invention provides non-mutagenic prodrug compounds of the formulas described herein that result in the inhibition of MMPs upon in vivo administration.


Find Patent Forward Citations

Loading…